Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
Date:4/1/2009

ts held-for-sale 470,547 - Deposits and other assets 147,826 377,798 ------- ------- Total assets $12,783,829 $53,245,938 =========== =========== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and other accrued liabilities $4,207,923 $4,515,426 Accrued compensation 537,215 2,225,868 Current portion of deferred rent 1,409,513 - Current portion of deferred revenue 27,083 1,227,031 Current portion of equipment financing - 953,940 --- ------- Total current liabilities 6,181,734 8,922,265 Non current portion of equipment financing - 1,352,684 Non-current portion of deferred rent 110,919 1,576,734 ------- --------- Total liabilities 6,292,653 11,851,683 Commitments Stockholders' equity: Common stock 3,441 3,437 Additional paid-in capital 322,671,604 320,579,240 Deferred stock-based compensation - (251,601) Accumulated other comprehensive income 7,841 69,262 Accumulated deficit (316,191,710) (279,006,083) ------------ ------------ Total stockholders' equity 6,491,176 41,394,255 --------- ---------- Total liab
'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... GliaCure, a privately-held biotechnology company focused ... and neuropsychiatric disorders based on glial targets, announced ... in a Phase 1b clinical trial of its ... a potential disease-modifying treatment. GliaCure,s innovative approach to ... both promotes the clearance of amyloid and stimulates ...
(Date:5/4/2015)... , May 4, 2015  Tikcro Technologies Ltd. ... annual report on Form 20-F for the fiscal year ... Exchange Commission ("SEC"). The annual report on Form 20-F ... of antibodies in the area of cancer immune checkpoints. ... qualities of high specificity and binding in targeting certain ...
(Date:5/4/2015)... 2015  Traverse Biosciences announced today that it ... agreement (CRADA) with Aratana Therapeutics Inc. (NASDAQ: ... for the treatment and control of periodontal disease ... Biosciences has also granted Aratana an exclusive option ... of periodontal disease in companion animals, inclusive of ...
(Date:5/4/2015)... /PRNewswire/ - Fluorinov Pharma (Fluorinov), a FACIT portfolio ... Dr. Roger J Garceau, to its Board of ... matters including corporate development and clinical strategy, his ... regulatory expertise as Fluorinov transitions to clinical development.  ... of pharmaceutical development experience to Fluorinov and most ...
Breaking Biology Technology:GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3
... Calif., March 31 Sigma-Aldrich (Nasdaq: ... high quality services and oligonucleotides to Gene Oracle, an ... the agreement, Sigma-Aldrich will be the exclusive supplier of ... will engage in co-marketing efforts to promote the GeneIOS ...
... Endo Pharmaceuticals (Nasdaq: ENDP ) announced ... the company,s board of directors. Dr. Hutson retired ... in various research and leadership positions with that company, ... Research and Development and director of Pfizer,s pharmaceutical R&D ...
... MYL ) today announced that Matrix Laboratories ... 71.2% controlling interest, has received the first tentative approval ... the President,s Emergency Plan for AIDS Relief (PEPFAR) for ... Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg.Mylan Vice Chairman ...
Cached Biology Technology:Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform 2Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform 3Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors 2Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors 3Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors 4Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R) 2
(Date:4/27/2015)... , April 27, 2015  For more than four ... show has been the premier worldwide event for the ... is a must-attend event for any local, national, or ... the emerging commercial markets and current applications of unmanned ... of this projected $48 billion industry, and how it ...
(Date:4/27/2015)... Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... pre-order customers the first week of May, 2015 and ... of May. Gino Pereira , ... for the company as Wocket® enters the consumer market. ...
(Date:4/27/2015)... Fla. , Apr. 27, 2015 Profile ... access control and security systems is pleased to announce ... company as a consultant and member of its scientific ... is widely known as a thought leader in technology-enhanced ... Learning Technology Group, and has published studies and books ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... German . To further enhance ... Forschungsgemeinschaft (DFG, German Research Foundation) has established twelve new ... DFG,s relevant Grants Committee in Bonn. The new Research ... training at a highly specialised level within a structured ...
... can incite the body to attack its own nerve ... both viral and nerve proteins. The dual-receptor observation suggests ... be triggered in susceptible young adults afflicted with multiple ... Immunology scientists Qingyong "John" Ji, Antoine Perchellet, and Joan ...
... University of Illinois at Chicago have discovered that an ... down and inhibiting the formation of excess scar tissue ... this week in Nature Cell Biology . ... "recruited" to the wound site that rapidly produce extracellular ...
Cached Biology News:DFG establishes 12 new research training groups 2DFG establishes 12 new research training groups 3DFG establishes 12 new research training groups 4DFG establishes 12 new research training groups 5DFG establishes 12 new research training groups 6Virus infection may trigger unusual immune cells to attack nerves in multiple sclerosis 2Virus infection may trigger unusual immune cells to attack nerves in multiple sclerosis 3Virus infection may trigger unusual immune cells to attack nerves in multiple sclerosis 4Researchers discover mechanism that limits scar formation 2
Request Info...
... The Luminex® 200 System with ... for developing single and multi-analyte assays ... contains the new, powerful user friendly ... user can design specific templates for ...
Recombinant Rat Leptin, CF...
... culture chambered coverslips are convenient ... staining and imaging. The chambered ... with standard optical-quality coverslips and ... to use. Preassembled CultureWell systems ...
Biology Products: